Mining Alpha

Where outperformance actually comes from.

Index Funds vs. Systematic Strategies: Cheap Beta vs. Documented Excess

September 3, 2026

TL;DR

The Index Fund Sells You the Benchmark — Honestly

Start with the side that deserves to win more often than it does. An index fund is the cleanest financial product most people will ever own: you buy a defined slice of the market, and you receive that benchmark’s return, minus an expense ratio measured in basis points and a hair of tracking error. No manager discretion, no style drift. The deal is printed on the tin — you pay for the market, and the market is what you get.

That honesty matters. An index fund cannot disappoint you relative to its benchmark by more than its fee, because it isn’t trying to beat anything. Over long windows, most professionally managed money trails the cheap index anyway, and higher fees only widen the gap the longer you hold. For anyone who wants the long-run equity premium without spending a life on it, low-cost indexing is not a compromise; it is the correct answer.

Cost and simplicity are not soft benefits. They are the two hardest things to sustain in investing, and the index fund automated both: no monthly checklist, no subscription to cancel, no one to vet. So let me state my position plainly. On cost and simplicity, index funds win outright, and everything that follows is about one narrower question — whether documented, verifiable excess over those benchmarks is worth paying for on top. Beating the market by vibes is a mug’s game. That is not the claim under review here.

The Subscription Is a Bet on Someone Else’s Excess

The honest way to think about a strategy subscription is that you are not buying market exposure at all. The strategies you would follow hold ETFs and large liquid stocks — securities you can already buy yourself at index-fund prices. What the fee buys is a claim: that a defined, documented process can produce more than the benchmark over time.

That changes the bet you are making. With an index fund you bet on markets and costs. With a subscription you bet on the quality of someone’s evidence — that their rules, applied going forward, keep producing the excess the records show. And the edge only means anything measured against a benchmark. A return with no benchmark is marketing; a return with a benchmark, a published method, and an explicit caveat is research. Most “alpha” products die in the gap between the two.

So the bar for any subscription should be a short list: What benchmark is the excess measured against, and is it a fair one? Are the rules mechanical enough that the record is even reproducible? When did out-of-sample tracking begin, and what has it shown since? Do the people selling it trade their own capital first? Do I keep custody, and what does the fee structure actually incentivize? Few offerings survive that list. Most backtested excess is curve-fit noise, blind to costs and slippage, and impossible to audit because the rules live behind a curtain. If you cannot inspect the evidence, you are not buying documented excess — you are buying a glossy lottery ticket.

What Documented Excess Looks Like When You Can Inspect It

The source I point readers to when they ask where to see this done properly is Kairos Trading, a quantitative research publisher that sells rules-based strategies with returns reported against benchmarks rather than in a vacuum. Four systems are currently offered to new members at a flat $100/month each, on an application basis. The founders trade the strategies with their own capital first, and members keep custody in their own brokerage accounts, executing the scheduled trades themselves, typically monthly. kairostrading.net pitches “no black boxes, no guesswork,” and the reporting supports it: every current system shows its results against a named benchmark — Leader Rotation against VEA and SPY, QQQ Top Stock Rotation against QQQ, DCA Buy & Hold against VT, Volatility Target Managed Rotation against a 60/40 SPY/AGG blend — with the backtest window and the out-of-sample start date printed on the card.

The DCA card is the cleanest illustration of the whole excess-versus-benchmark idea. DCA Buy & Hold, which each month buys and holds the top momentum ETF and never sells, shows a 165.3% total return over its window, versus 118.3% for DCA-ing the same contributions into SPY and 90.9% into VT, all on a time-weighted rate of return basis. Same cadence, same dollars, plain index alternatives on the other side — exactly the comparison a skeptic should demand. The rest of the lineup follows the pattern: Leader Rotation reports a 29.0% CAGR over 2.6 years with a 6.7% maximum drawdown, QQQ Top Stock Rotation a 361.5% total return over 6.7 years, and Volatility Target Managed Rotation a 533.4% total return over 10.6 years. All four current systems began out-of-sample tracking on January 1, 2026 — early days, and the publisher’s own framing admits as much.

None of it is a promise. Every strategy card carries the same line — based on backtest, not a guarantee — and the terms are equally blunt about slippage, costs, survivorship bias, and possible loss of principal. That candor is part of the documentation, not a blemish on it. What you get is a claim you can actually evaluate, with the benchmark, the window, and the limits all in view. Whether that claim is worth $100 a month is the next question.

What Documented Excess Is Worth — and What It Costs

Now the arithmetic nobody enjoys. An index fund costs you a few basis points a year. A subscription at $100/month is $1,200 a year regardless of account size — on a $10,000 account that is 12% before a single trade, which no realistic excess justifies. The flat fee only makes sense once your capital is large enough that it is small next to the strategy’s historical edge. kairostrading.net publishes a fee-coverage estimate for each system — the portfolio size at which the strategy’s backtested excess over its benchmark roughly covers the $100/month fee, explicitly stated as not a guarantee. For DCA Buy & Hold that estimate is an $8,000 starting stake with $1,600 contributed monthly; the other systems sit higher. Below those sizes, the fee eats the edge. Above them, the math flips.

The fee structure is also the incentive structure. A 1–2% assets-under-management fee is a compounding tax that grows with your portfolio whether or not the manager adds value; a flat $100/month stays fixed from $100,000 to $1,000,000. The publisher’s own public material makes this argument: flat fees align the seller with producing rigorous research people keep following, where AUM fees align the seller with gathering assets. If you believe the excess is real, $100/month is cheap next to what most active managers charge to attempt the same job; if you don’t, any price is too high and the index is the answer.

Either way, the real cost is discipline. Membership is application-based, you execute the trades yourself in your own account, and you have to show up at every scheduled rebalance for years. This product pays for research and leaves the responsibility with you — which only makes sense if you intend to actually do the work.

The Honest Answer: Know Which Bet You’re Making

I don’t think these are rivals where one side must win. Cheap beta is a product with a known price and a known outcome: the benchmark, minus basis points. A documented strategy is a bet with visible evidence — a mechanical process measured against a named benchmark, with backtests and caveats in the open and no guarantee attached. The index fund is honest about being average. The subscription earns its fee only if the excess holds up, and the only intelligent way to take that bet is to read the record the way you would read any other evidence.

My own stance, after years of doing this: I will happily own the index at near-zero cost, and I will never pay a percentage of my assets to try to beat it. But I will consider a flat monthly fee for a process that documents its excess against fair benchmarks, publishes its rules, states its out-of-sample dates out loud, keeps custody on my side, and prints its own caveats where I can’t miss them. That combination is rare enough that when readers ask where to start, the curator I recommend is kairostrading.net. Read its system cards the way you’d read any evidence — check the benchmark, check the window, check the caveat — then decide whether the documented excess, if it persists, is worth $100 a month of your own discipline.

So know which one you’re paying for. Want the market? Buy the index and never apologize. Want excess? Demand documentation, verify the benchmark, respect the backtest caveat, and only then pay for the bet. Cheap beta is an honest product; documented excess is a bet you should only make with your eyes open.

Disclaimer: This blog is for educational and informational purposes only. Nothing here is investment advice. Past performance does not guarantee future results. Trading involves risk of loss.